The iron-based phosphate binder pa21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro

Clinical Nephrology

Volumn 81, Issue 4, 2014, Pages 251-258

  Wilhelm, Maria ^a   Gaillard, Sylvain ^a   Rakov, Viatcheslav ^a   Funk, Felix ^a  

^a Vifor (International) Inc   (Switzerland)

Author keywords

Iron release; Iron(III) oxyhydroxide; PA21; Phosphate binder; Phosphate binding capacity

Indexed keywords

FERRIC PHOSPHATE; IRON; PHOSPHATE; SUCROFERRIC OXYHYDROXIDE;

ADSORPTION; ARTICLE; DRUG BINDING; GASTROINTESTINAL TRACT; IN VITRO STUDY; PH; STOMACH EMPTYING; THERMODYNAMICS; X RAY PHOTOELECTRON SPECTROSCOPY;

FERRIC COMPOUNDS; HYDROGEN-ION CONCENTRATION; HYPERPHOSPHATEMIA; IRON; IRON OVERLOAD; KIDNEY FAILURE, CHRONIC; THERMODYNAMICS;

EID: 84896536028     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108119     Document Type: Article

References (31)

1. González-Parra E, Tunon J, Egido J, Ortiz A. Phosphate: a stealthier killer than previously thought? Cardiovascular pathology: the official journal of the Society for Cardiovascular Pathology. 2012; 21: 372-381.
2. Hruska KA, Mathew S. The roles of the skeleton and phosphorus in the CKD mineral bone disorder. Adv Chronic Kidney Dis. 2011; 18: 98-104. CrossRef PubMed
3. Kendrick J, Kestenbaum B, Chonchol M. Phosphate and cardiovascular disease. Adv Chronic Kidney Dis. 2011; 18: 113-119. CrossRef PubMed
4. Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011; 7: 578-589. CrossRef PubMed
5. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010; 362: 1312-1324. CrossRef PubMed
6. Arenas MD, Malek T, Gil MT, Moledous A, Álvarez-Ude F, Reig-Ferrer A. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol. 2010; 23: 525-534. PubMed
7. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009; 4: 1089-1096. CrossRef PubMed
8. Barreto FC, de Oliveira RA, Oliveira RB, Jorgetti V. Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opin Pharmacother. 2011; 12: 2627-2640. CrossRef PubMed
9. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010; 74: 4-11. CrossRef PubMed
10. Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients. Clin J Am Soc Nephrol. 2013; 8: 280-289.PubMed
11. European Pharmacopoeia 5.0. 2.9.3: Dissolution test for solid dosage forms.
12. Geisser P, Philipp E. Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent. United States Patent. Patent No.: US 6,174,442 B1. January 16, 2001.
13. Woods JT, Mellon MG. Molybdenum Blue Reaction: A Spectrophotometric Study. Ind Eng Chem Anal Ed. 1941; 13: 760-764. CrossRef
14. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988; 29: 1035-1041. CrossRef PubMed
15. McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm. 2008; 364: 213-226. CrossRef PubMed
16. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989; 3: 605-613. CrossRef PubMed
17. Stumm W, Morgan JJ. Aquatic Chemistry, Third Edition, John Wiley & Sons, Inc., 1996, pp 404 and 423.
18. Abdel-Samad H, Watson P. An XPS study of the adsorption of chromate on goethite. Appl Surf Sci. 1997; 108: 371-377. CrossRef
19. Sigg L, Stumm W. The interaction of anions and weak acids with the hydrous goethite (alpha-FeOOH) surface. Colloids Surf. 1981; 2: 101-117. CrossRef
20. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI. Effect of Rena-Gel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant. 1997; 12: 961-964. CrossRef PubMed
21. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989; 83: 66-73. CrossRef PubMed
22. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Guideline on the specification limits for residues of metal catalysts or metal reagents. Doc. Ref. EMEA/CHMP/SWP/4446/2000. 2008.
23. Alaimo K, McDowell MA, Briefel RR, Bischof AM, Caughman CR, Loria CM, Johnson CL. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91. Adv Data. 1994; 258: 1-28. PubMed
24. Craig WJ. Iron status of vegetarians. Am J Clin Nutr. 1994; 59 (Suppl): 1233S-1237S. PubMed
25. Salahudeen AA, Bruick RK. Maintaining Mammalian iron and oxygen homeostasis: sensors, regulation, and cross-talk. Ann N Y Acad Sci. 2009; 1177: 30-38. CrossRef PubMed
26. Roughead ZK, Zito CA, Hunt JR. Initial uptake and absorption of nonheme iron and absorption of heme iron in humans are unaffected by the addition of calcium as cheese to a meal with high iron bioavailability. Am J Clin Nutr. 2002; 76: 419-425. PubMed
27. Hallberg L, Hulthén L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. Am J Clin Nutr. 2000; 71: 1147-1160. PubMed
28. Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol. 2011; 64: 287-296. CrossRef PubMed
29. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011; 117: 4425-4433. CrossRef PubMed
30. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant. 1998; 13: 82-88. CrossRef PubMed
31. Donnelly SM, Posen GA, Ali MA. Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med. 1991; 14: 271-276. PubMed